#United States #Burlington #SQ Innovation #Furosemide API #FIS Fabbrica

Overview of the Partnership

On April 15, 2026, SQ Innovation, renowned for its innovations in the biopharmaceutical sector, and FIS Fabbrica Italiana Sintetici S.p.A., a leading player in the pharmaceutical ingredient arena, announced a significant strategic partnership. This collaboration aims to secure a consistent supply of high-quality furosemide, crucial for their flagship product, Lasix® ONYU, and future pharmaceutical ventures. With a shared commitment to enhancing patient care globally, this alliance positions both companies for substantial growth and long-term success.

The Importance of Furosemide API

Furosemide is a loop diuretic widely used to treat edema, particularly in patients suffering from chronic heart failure. By ensuring the availability of pharmaceutical-grade furosemide, this agreement allows SQ Innovation to continue offering effective alternatives that can minimize hospital stays for patients. SQ Innovation is dedicated to developing innovative therapies that support at-home treatment options, thereby increasing patient comfort and accessibility.

Details of the Agreement

Under this strategic agreement, FIS will provide SQ Innovation with furosemide, facilitating the ongoing production of the Lasix ONYU infusion system. Approved by the FDA in 2025, Lasix ONYU integrates advanced technology to deliver furosemide more effectively than previous intravenous methods. Importantly, this partnership includes exclusivity provisions, underlining the critical nature of FIS's role in supporting SQ Innovation's supply chain and product distribution.

Pieter Muntendam, MD, Founder and CEO of SQ Innovation, emphasizes, "Securing a reliable supply of high-quality furosemide API is critical to our mission of providing innovative heart failure treatment options that aim to provide an alternative to hospitalizations." This assurance of quality and reliability is essential in the healthcare landscape, where access to effective medications can directly impact patient outcomes.

Enhancing Treatment for Heart Failure

Lasix ONYU represents a breakthrough in treating chronic heart failure, utilizing a unique delivery system that allows patients to go about their daily lives while receiving necessary medical treatment. This innovative drug-device combination allows for a controlled administration of furosemide, presenting a viable alternative to standard intravenous therapies and significantly improving the quality of life for patients.

FIS's Manufacturing Excellence

FIS, a respected name in API manufacturing, aligns perfectly with SQ Innovation's standards for quality. With a robust infrastructure and advanced manufacturing capabilities, FIS ensures that SQ Innovation can meet both current demand and future needs for furosemide and additional pipeline products. Daniele Piergentili, CEO of FIS, shares, "We are proud to partner with SQ Innovation in advancing transformative solutions for heart failure treatment. By merging our advanced manufacturing expertise with strict quality standards, we can create a steadfast supply foundation for innovative products.

Conclusion

The collaboration between SQ Innovation and FIS signals a significant step forward in ensuring that critical medications like furosemide are readily available to those who need them most. As healthcare continues to evolve, partnerships like this will become essential to enhancing the quality and accessibility of treatments worldwide. Both companies stand poised to make a profound impact on the lives of patients dealing with heart failure, exemplifying the essence of innovation and strategic alignment in the pharmaceutical industry.

For more information on Lasix ONYU, including safety information and usage instructions, interested readers are encouraged to visit www.lasix-onyu.com.